Etopophos (etoposide phosphate) powder for injection vials and Vepesid etoposide capsules
Consumers and health professionals are advised that there are current shortages of Etopophos etoposide 1 g (as phosphate) and Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vials and Vepesid etoposide 50 mg capsule blister packs.
The shortage of Vepesid etoposide 100 mg capsule blister pack has been resolved.
Additionally, alternative products that were previously available are no longer available.
The information and table below have been updated with new information.
For further information please contact the product sponsors.
Medicine shortages - anticipated
28 June 2016
Consumers and health professionals are advised that there are anticipated shortages of Etopophos etoposide 1 g (as phosphate) and Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vials and Vepesid etoposide 50 mg and 100 mg capsule blister packs.
All products are used for treatment of:
- small cell carcinoma of the lung
- acute monocytic and myelomonocytic leukaemia
- Hodgkin's disease
- Non-Hodgkin's lymphoma.
Etopophos injection vials are also indicated for the treatment of testicular tumours.
The sponsor, Bristol-Myers Squibb, has advised the TGA that the shortage is due to an unexpected interruption in the supply of the medicine's active pharmaceutical ingredient.
The affected products are:
|ARTG No||ARTG Label||Sponsor||Status|
|57483||Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vial||Bristol-Myers Squibb Australia||Unavailable until 1 April 2017|
|77220||Etopophos etoposide 1 g (as phosphate) powder for injection vial||Bristol-Myers Squibb Australia||Unavailable until 1 April 2017|
|10233||Vepesid etoposide 50 mg capsule blister pack||Bristol-Myers Squibb Australia||Out of stock from 28 February 2017 until 1 April 2017|
|10234||Vepesid etoposide 100 mg capsule blister pack||Bristol-Myers Squibb Australia||Available|
Information for consumers
If you have any questions or concerns about this issue, talk to your health professional.
Information for health professionals
Health professionals are advised to take these expected shortages into account when planning treatment with Etopophos injection vials or Vepesid capsules.
If you intend to switch a patient from the oral to injectable form of etoposide, please note the absolute bioavailability of oral etoposide is approximately 55% with considerable variations between subjects (17-74%). Dosage adjustments may be required.
Please refer to the full prescribing information for injectable etoposide alternatives available at:
For information on the Medicine Shortages Information Initiative please contact the TGA via email at email@example.com or call 1800 020 653.
Consumers and health professionals are encouraged to report problems with medicines, vaccines or medical devices. Your report will contribute to the TGA's monitoring of these products.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine, vaccine or medical device.